Pharma Industrial India Magazine - May-June 2024

player in API CDMO services, with cost-effective manufac- turing capabilities and a sizeable labor pool of highly trained professionals. Strengths • Generic API Development: Generic versions of off-patent drugs can be developed using generic APIs. • Cost-Effective Manufacturing: India’s manufacturing fa- cilities are cost-effective, providing a competitive edge in the global market. • Trained Professionals: The availability of a large pool of highly trained scientific and technical professionals is a sig - nificant strength. Opportunities • API Manufacturing: Development of API manufacturing en- ables the growth of CDMO players catering to this segment. • Biosimilars Market: The India Biosimilars market size was valued at USD 349 million in 2022 and is estimated to grow at a CAGR of approximately 25% to reach USD 2.1 billion by 2030. Regulatory Framework CRAMS players in India deal with multiple regulatory bodies depending on their product portfolio, including: • Ministry of Health and Family Welfare • Central Drugs Standard Control Organization (CDSCO) • Indian Council of Medical Research (ICMR) • Department of Biotechnology (DBT) • Pharmaceutical Export Council (Pharmexcil) • Controller General of Patents Compliance with regulations such as GMP is crucial for CRAMS operations. The regulatory framework ensures quality control, validation of test protocols, and coordination with state and city authorities. Conclusion The Indian CRAMS industry is poised for significant growth, driven by factors such as increasing outsourcing trends among pharmaceutical companies, complex drug develop- ment programs, and cost-effective manufacturing solutions. To capitalize on these opportunities, Indian CRAMS companies are focusing on enhancing their capabilities, investing in inno- vation, and strengthening their global presence to maintain a competitive edge in the evolving pharmaceutical landscape. ANRETWICSLE PHARMA INDUSTRIALINDIA · MAY-JUN 24 28